Valeant goes after Allergan
An article in the Toronto Star titled Patents drive blockbuster deals in drug industry
discusses the $45 billion (U.S.) joint offer of Valeant with U.S. activist investor Bill Ackman for Botox maker Allergan Inc.
Within the article:
“Rather than fighting each other in all areas, which hurts profit margins, big pharma companies will streamline their portfolios and specialize more to boost their bottom line,” Enrique Quemada, head of the Madrid-based advisory firm OnetoOne Corporate Finance, told Bloomberg.
discusses the $45 billion (U.S.) joint offer of Valeant with U.S. activist investor Bill Ackman for Botox maker Allergan Inc.
Within the article:
“Rather than fighting each other in all areas, which hurts profit margins, big pharma companies will streamline their portfolios and specialize more to boost their bottom line,” Enrique Quemada, head of the Madrid-based advisory firm OnetoOne Corporate Finance, told Bloomberg.
posted by Lawrence B. Ebert at 8:47 PM
0 Comments:
Post a Comment
<< Home